TX-MAVENIR
12.4.2022 09:02:15 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the collaboration with Aspire Technology (Aspire), a specialized Network Solutions developer and System Integrator, to accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) leveraging Aspire’s Open Networks Lab in Europe.
Communication Service Providers (CSPs) demand for integrated high performing Open Radio Access Network (Open RAN) solutions based on Mavenir O-RAN compliant cloud-native Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks is growing fast, fueled by modernization and coverage expansion projects, as well as private networks and indoor projects.
The number of O-RAN compliant RRUs from partners globally is also growing with sophisticated products across the different radio technologies, including Massive MIMO (mMIMO) and millimeter Wave (mmWave).
Mavenir and Aspire will be leveraging Aspire’s Open Networks Lab in Dublin for third-party RRU integration and testing. Furthermore, RRU vendors will be able to engage directly with Aspire and fast-track the integration and testing of new O-RAN compliant radios and frequency variants with Mavenir CU/DU software.
This collaboration will benefit not only RRU vendors, but also CSPs by expanding the offering of innovative and high-performing solutions supporting a wide number of use cases.
“This partnership greatly enhances the capacity to integrate and test RRUs with Mavenir’s CU/CU for 4G and 5G,” said Puneet Sethi, SVP/GM RAN Business for Mavenir. “Open RAN has accelerated to a point that we need to continuously innovate to be ahead of demand, including go-to-market models. Our RRU partners want to get their newest products available for deployment, and CSPs want to take full advantage of a fast-paced ecosystem minimizing integration and testing effort. We are continuously expanding our partner eco-systems for RRU integration to respond to the evolving market needs with specialized high-quality services and fast turnaround.”
Declan Friel, CTO, Aspire said; “We are delighted to extend our relationship with Mavenir. Aspire’s heritage in software engineering and testing of complex radio products carried over into Open RAN, combined with global CSP experience through design, optimization and support of live networks, uniquely positions us to accelerate the availability of new ORAN compliant solutions for wide market adoption. As a European-based independent company, and with our Open Networks Lab in Ireland today supporting a number of global clients and partners, our focus has been to accelerate the ORAN ecosystem development and to support CSPs. This will allow them to fully realize the benefits of Telco Cloud, Service Management & Orchestration and Open RAN, in terms of flexibility, performance and cost.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Aspire:
Aspire Technology is a leading Specialized System Integrator with a long history and experience in fixed and mobile networks, and Open RAN since its early days. Aspire’s clients are spread around the Globe and benefit from their advanced services and software automation solutions. The Aspire Open RAN Lab enables technology partners and communications service providers to fasttrack development, integration, benchmarking, testing and deployment of Open RAN based networks and solutions. Aspire has been actively contributing to acceleration of time to market, reduction of deployment cost and improvement of multivendor interoperability and network performance. www.aspiretechnology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom